Good evening , Dr. Rivera .

Immunology and skinPhase 1

3 candidates·0 to review

Atopic Dermatitis

Dupixent

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Ages: 18+
Sex: All
Enrolling: 40
Ends: Dec 2024

3 candidates·0 to review

Healthy Volunteer

REGN20423

This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is…

Ages: 18–65
Sex: All
Enrolling: 144
Ends: Jun 2028

0 candidates·2 to review

Atopic Dermatitis

Dupilumab

Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will…

Ages: 18+
Sex: All
Enrolling: 30
Ends: Dec 2026

No candidates in your panel· 13

Open trials where none of your patients pre-screened as a candidate or for chart review, or that haven't been pre-screened yet.

Immunology and skinPhase 3

Juvenile Idiopathic Arthritis

Sarilumab SAR153191 (REGN88)

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the…

Ages: 1–17
Sex: All
Enrolling: 51
Ends: Mar 2028

Immunology and skinPhase 3

Eosinophilic Esophagitis

Dupilumab

This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study…

Ages: 0.5–6
Sex: All
Enrolling: 20
Ends: Jun 2028

Prurigo Nodularis

Dupilumab

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment period: 24 weeks. * Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including…

Ages: 0.5–17
Sex: All
Enrolling: 18
Ends: Oct 2027

Immunology and skinPhase 1

CHAPLE Disease

Pozelimab

This study is researching a drug called pozelimab (called "study drug"). The main aim of this study is to monitor the safety and tolerability of the study drug. The study is focused on young children 1 to 5 years of age, who have CHAPLE disease. CHAPLE is a very rare hereditary disease that can cause potentially…

Ages: 1–5
Sex: All
Enrolling: 5
Ends: Feb 2030

Lupus Nephritis

Odronextamab

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study,…

Ages: 18–60
Sex: All
Enrolling: 90
Ends: Sep 2029

No candidates in your panel

Pruritis

Dupilumab

The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.

Ages: 18–60
Sex: All
Enrolling: 46
Ends: Jan 2026

Eosinophilic Esophagitis

Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE…

Ages: 22+
Sex: All
Enrolling: 30
Ends: Sep 2026

Immunology and skinPhase Early 1

Hidradenitis Suppurativa

Olatorepatide

This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS). In this study, olatorepatide is being tested in people with HS and living with overweight or obesity to see if it helps improve their HS symptoms and quality of life and…

Ages: 18+
Sex: All
Enrolling: 300
Ends: Nov 2028

Immunology and skinPhase 1–2

Sporadic Inclusion Body Myositis

Pozelimab/Cemdisiran

To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM

Ages: 45–75
Sex: All
Enrolling: 10
Ends: May 2027

Rheumatoid Arthritis

Sarilumab, SAR153191 SC

This is a Phase 1/Phase 2 study with: * 5-arms design for Part A; * and a single arm for Part B. The purpose of this study is to measure PK parameters and safety with sarilumab intravenous (IV) with or without concomitant oral conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in male and female…

Ages: 18+
Sex: All
Enrolling: 140
Ends: Oct 2028

Alopecia Areata

Dupilumab

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA…

Ages: 18+
Sex: All
Enrolling: 76
Ends: Nov 2027

Polymyalgia Rheumatica

Sarilumab

This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 4, 3-group study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week prednisone taper, is superior to placebo given with a 52-week prednisone taper in…

Ages: 50+
Sex: All
Enrolling: 300
Ends: Jun 2029